Passage Bio (PASG) Price & Analysis

Compare

644 Followers

PASG Stock Chart & Stats

$9.59

>-$0.01(-0.86%)

At close: Jan 08 4:00 PM EST

$9.59

>-$0.01(-0.86%)

Day’s Range― - ―

52-Week Range$5.12 - $20.20

Previous CloseN/A

Volume182.24K

Average Volume (3M)41.18K

Market Cap

$29.92M

Enterprise Value-$2.91M

Total Cash (Recent Filing)$52.77M

Total Debt (Recent Filing)$24.34M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Mar 09, 2026

EPS Estimate

-2.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.44

Shares Outstanding3,120,295

10 Day Avg. Volume55,130

30 Day Avg. Volume41,182

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.56

Price to Sales (P/S)0.00

P/FCF Ratio-0.71

Enterprise Value/Market Cap-0.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit3.17

Enterprise Value/Ebitda0.07

Forecast

1Y Price Target

$40.33

Price Target Upside320.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsSustained CSF PRGN expression and NfL reduction are strong biomarkers, suggesting prevention of neurodegeneration from PBFT02 treatment.

Financial PerformanceThe new price target of $32 continues to suggest a strong upside, and the Outperform rating on PASG is reiterated.

Regulatory ProgressFDA is expected to agree on a single-arm registrational study due to high unmet medical need in FTD and newly published guidelines on cell and gene therapy.

Bears Say

Safety ConcernsThe company also saw a fourth SAE (pulmonary embolism) in the first dose 2 patient, prompting the recent filing of an amended safety protocol.

Passage Bio News

Passage Bio initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price...

26d ago

PASG

PASG Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Passage Bio, Inc. (PASG) is scheduled to report 3rd quarter earnings on 11/18/2025, after the market closes. Regarding...

1M ago

PASG

3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts

Looking for top-rated biotech stocks to buy now? Recent analyst updates highlight three companies that have earned Strong...

1M ago

UPB

BNTX

Passage Bio’s Growth Potential Highlighted by Clinical Progress and Regulatory Alignment

Yun Zhong, an analyst from Wedbush, reiterated the Buy rating on Passage Bio. The associated price target was...

1M ago

PASG

Passage Bio Reports Q3 Financial Results and Updates

The latest announcement is out from Passage Bio ( ($PASG) ). On November 10, 2025, Passage Bio reported...

1M ago

PASG

Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)

“We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient...

1M ago

PASG

Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia

Passage Bio, Inc. (($PASG)) announced an update on their ongoing clinical study. Study Overview: Passage Bio, Inc. is...

2M ago

PASG

Optimistic Outlook for Passage Bio’s PBFT02: Promising Data and Potential FDA Support

Passage Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from...

2M ago

PASG

Promising Developments and Strong Financial Outlook Reinforce Buy Rating for Passage Bio

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Passage Bio, boosting the price target to $40.00....

4M ago

PASG

Passage Bio price target lowered to $67 from $260 at Canaccord

Canaccord lowered the firm’s price target on Passage Bio (PASG) to $67 from $260 and keeps a Buy...

4M ago

PASG

Passage Bio Reports Q2 2025 Progress and Financials

Passage Bio, Inc. ( ($PASG) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

PASG

Passage Bio Reports Promising Q2 2025 Financial Results

An update from Passage Bio ( ($PASG) ) is now available. On August 12, 2025, Passage Bio reported...

4M ago

PASG

Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year

“We continue to be encouraged by the emerging data from our upliFT-D clinical trial, which underscore the potential...

4M ago

PASG

Passage Bio expects cash to fund operations into Q1 of 2027

Cash, cash equivalents and marketable securities were $57.6 million as of June 30, 2025, as compared to $91.8...

4M ago

PASG

PASG FAQ

What was Passage Bio’s price range in the past 12 months?

Passage Bio lowest stock price was $5.12 and its highest was $20.20 in the past 12 months.

What is Passage Bio’s market cap?

Passage Bio’s market cap is $29.92M.

When is Passage Bio’s upcoming earnings report date?

Passage Bio’s upcoming earnings report date is Mar 09, 2026 which is in 79 days.

How were Passage Bio’s earnings last quarter?

Passage Bio released its earnings results on Nov 18, 2025. The company reported -$2.44 earnings per share for the quarter, beating the consensus estimate of -$2.758 by $0.318.

Is Passage Bio overvalued?

According to Wall Street analysts Passage Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Passage Bio pay dividends?

Passage Bio does not currently pay dividends.

What is Passage Bio’s EPS estimate?

Passage Bio’s EPS estimate is -2.57.

How many shares outstanding does Passage Bio have?

Passage Bio has 3,120,295 shares outstanding.

What happened to Passage Bio’s price movement after its last earnings report?

Passage Bio reported an EPS of -$2.44 in its last earnings report, beating expectations of -$2.758. Following the earnings report the stock price went down -7.512%.

Which hedge fund is a major shareholder of Passage Bio?

Currently, no hedge funds are holding shares in PASG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Passage Bio

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio (PASG) Earnings & Revenues

Historic Earnings Reports

PASG Stock 12 Month Forecast

Average Price Target

$40.33

▲(320.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","69":"$69","20.25":"$20.3","36.5":"$36.5","52.75":"$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20.25,36.5,52.75,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,12.32,16.96,21.599999999999998,26.24,30.88,35.519999999999996,40.16,44.8,49.44,54.08,58.72,63.35999999999999,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,10.19153846153846,12.703076923076923,15.214615384615385,17.726153846153846,20.237692307692306,22.74923076923077,25.26076923076923,27.77230769230769,30.283846153846152,32.79538461538461,35.30692307692308,37.818461538461534,{"y":40.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,8.704615384615384,9.72923076923077,10.753846153846155,11.778461538461539,12.803076923076922,13.827692307692308,14.852307692307694,15.876923076923077,16.90153846153846,17.926153846153845,18.950769230769232,19.975384615384616,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >